Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203966 | 1.00 | ALDH1A1 (0.36) | ALDH1A1GRIA4CYP2D6CYP2C9HIF1A | |
| SCHEMBL11987754 | 0.78 | FAAH (0.42) | ALDH1A1CYP2D6CYP2C9HIF1ATDP1 | |
| SCHEMBL1204002 | 0.78 | LMNA (0.46) | ALDH1A1CYP2D6CYP2C9TDP1CYP3A4 | |
| SCHEMBL26015528 | 0.74 | ALDH1A1 (0.37) | ALDH1A1TDP1TP53CYP3A4ALOX15 | |
| SCHEMBL17970204 | 0.70 | MAPT (0.34) | ALDH1A1TDP1TP53CYP3A4ALOX15 | |
| SCHEMBL11987758 | 0.68 | ALOX5 (0.43) | ALDH1A1TSHRSMN1; SMN2MMP1MMP2 | |
| SCHEMBL28671135 | 0.66 | TDP1 (0.44) | ALDH1A1GRIA4CYP2D6CYP2C9TDP1 | |
| SCHEMBL28291528 | 0.66 | TDP1 (0.48) | ALDH1A1HIF1ATDP1TP53CYP3A4 | |
| SCHEMBL27513027 | 0.65 | EPHX1 (0.42) | ALDH1A1CYP2C9HIF1ATDP1TSHR | |
| SCHEMBL2852282 | 0.63 | PTGS2 (0.61) | ALDH1A1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188267-B1 | SUBSTITUTED AMIDES, METHODS OF MAKING, USE THEREOF FOR THE TREATMENT OF DISEASES SUCH AS CANCER | GILEAD CONNECTICUT INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8247550-B2 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247550-B2 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884108-B2 | tyrosine kinase inhibitors such as N-(3-(6-(4-(1,4-Dimethyl-3-oxopiperazin-2-yl)phenyl amino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-fluorophenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide for treating bone disorders, allergic disorders, autoimmune diseases, inflammatory diseases | CGI PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059944-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | ALDH1A1 3393/4885GRIA4 3394/4885CYP2D6 1632/4885 |
| US-20090082330-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | ALDH1A1 3393/4885GRIA4 3394/4885CYP2D6 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.